Sigvotatug Vedotin

DB18377InvestigationalProtein Based Therapies

Sigvotatug vedotin (SGN-B6A) is a humanized immunoglobulin G1 anti-integrin beta-6 monoclonal antibody conjugated to monomethyl auristatin E.

Mechanism
Curator reviewed
Code names
PF-08046047 · SGN-B6A

Resolves to

Compound
UNIIQX0ONY0O9TCAS2764774-91-4
Targets
P18564ITGB6

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Sigvotatug Vedotin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In